Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

Publisher： Karger

E-ISSN： 1423-0232|87|1|7-20

ISSN： 0030-2414

Source： Oncology, Vol.87, Iss.1, 2014-06, pp. : 7-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study

By  

Oncology Research and Treatment, Vol. 33, Iss. 12, 2010-11 ,pp. : 684-690

Karger

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 210-213

Karger

Access to resources Recommend Favorite

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 353-359

Karger

Access to resources Recommend Favorite